(San Francisco, CA) Benchling is unique; because, it is the first business to have successfully developed a life sciences research, and, development internet cloud. This research and development internet cloud permits the acceleration, measurement and forecast of research and development. In other words, and as it relates to the life sciences sector of the economy; Benchling is the home of discovery, all the way through, bio-processing. The previously said is all done at, Benchling.com. Additionally, Benchling.com is a software as a service (SaaS), website or platform. This side of the business is best described by its three parts; applications, platforms and services. Recently, Benchling announced that, it has plans to continue being the home of life sciences discoveries. Specifically, the aforementioned business revealed that, it has secured $34.5 million USD in a Series C funding round. As part of the funding round, current investors decided to double down on their bet. The investors who decided to double down on their bet are Benchmark, and, Thrive Capital. The most noteworthy new investors of Benchling are Menlo Ventures, Lead Edge Capital and Y Combinator Continuity.
Y Combinator Continuity, Lead Edge Capital and Menlo Ventures as the most noteworthy new investors will be contributing funds. The funds will be used for the following two things. The two things are the continuation of the current growth trajectory, and, international expansion. In reference to, the continuation of the current growth trajectory, the aforementioned is best described in this way. One year ago, Benchling successfully closed a Series B funding round. Since then; the revenue has tripled, the customers have tripled and there are more than one hundred industry businesses or educational institutions who are clients. In reference to, international expansion, the aforementioned is planned to be aggressive. Benchling is completely committed to an international expansion. The way it is planned the international expansion will be characterized by a global sales growth of the product, successful execution of product sales leads and successful development of commercial relationships.
However and returning to; Benchling.com, the aforementioned and as previously said, is best described by its three parts. The three parts are; applications, platforms and services. The applications part of the website, is best characterized as, a suite of six natively unified applications. The latter, are credited with accelerating life sciences research and development, at all levels. The platforms part of the website, is best characterized as; codeless configuration, open integration and dashboards. The latter, is how a life sciences business actually does work on Benchling.com. The work that is done, through the website, ends up being tailored to the subscribing business. The service part of the website, is best characterized as, consulting services. Through comprehensive life sciences research and development consulting, Benchling.com, attempts to guarantee success for the subscribing business.
Jed Dean is a Co-Founder and the Vice President of Operations & Engineering at Zymergen. Through a press statement, Mr. Dean said the following. “Zymergen is unlocking new sources of molecular diversity to help engineer new products from biomaterials to pharmaceuticals. As a technology leader ourselves, we were looking for a software platform that is leading the way in facilitating cutting-edge science. Benchling has been an invaluable technology partner as we’ve scaled our business. It has advanced data-sharing, innovation, and collaboration across our teams.” Matt Murphy is a Partner of Menlo Ventures. Through a press statement, Mr. Murphy said the following. “Life science R&D has become incredibly complex—from the molecules to the processes to the multi-dimensional data. Until Benchling, there had been no end-to-end, purpose-built SaaS application to enhance, streamline, and drive collaboration across R&D teams. Biologics are the future of life sciences and the faster that innovation gets to market, the more society benefits.” Matt Murphy also said. “Benchling’s software replaces pen and paper workflows and becomes the system of record for a wide range of biotech and pharma R&D projects—from medicine and cancer treatment to plant-based meat and sustainable materials. Saji and team’s first-hand experience in life sciences, combined with their passion for building better software to accelerate innovation, has delivered a game-changing platform for leading commercial and academic institutions.”
To end, Benchling or Benchling.com did release a press statement. Sajith Wickramasekara is a Co-Founder and the Chief Executive Officer of Benchling. Through a press statement, Mr. Wickramasekara said the following. “Benchling was created for today’s researchers who are working on tomorrow’s science, allowing them to focus on achieving the next breakthrough outcomes. The next generation of scientists is already on Benchling and at the forefront of establishing the future of the life science and biotech industries. We’ll use this investment to support deeper engagements with large commercial customers and bring the power of the cloud to tackle the complexity of biotech.” As previously stated, Benchling recently announced that, it has plans to continue being the home of life sciences discoveries. Specifically, the aforementioned business revealed that, it has secured $34.5 million USD in a Series C funding round. As part of the funding round, current investors decided to double down on their bet. The investors who decided to double down on their bet are Benchmark, and, Thrive Capital. Lastly; the most noteworthy new investors of Benchling are Menlo Ventures, Lead Edge Capital and Y Combinator Continuity.
###
Written from Press Release
Registered Writer with
PR Newswire Association, LLC
R-Berumen28
07/27/2019
Post a Comment